Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
MIST's Cardamyst demonstrated rapid efficacy, favorable safety, and potential to reduce costly emergency visits, supporting robust market adoption. With over $150 million in cash, minimal near-term dilution risk, and nearly $1 net cash per share, MIST offers a highly asymmetric risk-reward. Expansion into pediatric, European, and AFib-RVR markets could multiply Cardamyst's addressable market, none of which is priced into MIST's current valuation. canart7/E+ via Getty Images Milestone Pharmaceuticals Inc. ( MIST ) was founded in 2003 and is based, jointly, in both Montreal and Charlotte, with its 30+ employees split between both locations. It is an early-stage biotech company that has developed a nasal spray based on This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of MIST either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compen
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines AgencyGlobeNewswire
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MIST&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WallMarketBeat
- Aptar's Bidose Nasal System Delivers CARDAMYSTâ„¢ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]Yahoo! Finance
MIST
Earnings
- 11/12/25 - Beat
MIST
Sec Filings
- 1/13/26 - Form 8-K
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- MIST's page on the SEC website